A benchtop examination of 3-chloro-6-methoxycarbonyl-1,2-benzisothiazole typically begins with a lot-specific certificate of analysis quantifying purity via reversed-phase HPLC on a 150 mm × 4.6 mm, 5 µm C18 column (mobile phase acetonitrile/0.1% trifluoroacetic acid 60:40, UV detection at 254 nm). Acceptable lot purity floor is set at ≥ 98.5% area normalization, with a specification for the dominant dimeric impurity—the symmetrical disulfide formed by oxidative coupling of the thiolate generated during storage—held below 0.8%. Water content, determined by volumetric Karl Fischer titration per USP 〈921〉 Method Ia, is controlled to ≤ 0.3%, as moisture ingress above 0.5% has been observed on pilot-plant isolations to accelerate hydrolytic ring-opening to the corresponding 2-sulfanylbenzamide ester within 48 h at 25 °C. The ester functionality is acid-labile; residual strong-acid content after quench, monitored as chloride ion by ion chromatography (DIN EN ISO 10304-1), must not exceed 50 ppm to prevent autocatalytic decomposition during drummed storage under nitrogen.
Why Does the Chloro Substituent Dictate Reaction Manifold Selection Over Its Bromo Congener?
Selecting 3-chloro-6-methoxycarbonyl-1,2-benzisothiazole instead of the corresponding 3-bromo or 3-iodo analogue is rarely a decision of synthetic convenience; it is a direct consequence of chemoselectivity requirements in the presence of the ring-sulfur electrophilic center. In palladium-catalyzed cross-couplings, the C–Cl bond (bond dissociation energy ca. 400 kJ mol⁻¹ versus 340 kJ mol⁻¹ for C–Br) retards oxidative addition to a degree that allows selective functionalization of a co-halogenated coupling partner or avoids competitive activation of the benzoisothiazole ring in one-pot, multi-component sequences. High-throughput screening on a 24-position parallel reactor block using XPhos Pd G3 (2 mol%) and K₃PO₄ in THF/water at 60 °C showed complete conversion of the 3-bromo analogue with 4-methoxyphenylboronic acid in 2.5 h, whereas the 3-chloro scaffold required 18 h and 80 °C to reach >95% conversion, confirming the kinetic window exploited in stepwise elaborations. Published data for this specific configuration is limited, but in analogous 3-halo-1,2-benzisothiazole 1,1-dioxides, the chloro derivative’s inertness toward SNAr with secondary amines at 25 °C allows late-stage amination of the 6-position without competing displacement, a path precluded by the bromo derivative which yields a 3:1 mixture of 3- and 6-aminated products under the same conditions (DIPEA, DMF, 12 h).
Cost structure reinforces the kinetic argument. Spot market pricing tabulations from eastern seaboard chemical distributors in Q2 2024 placed the 3-chloro variant at approximately 65% of the 3-bromo cost per mole on a >1 kg scale, a differential magnified by the bromo compound’s requirement for stabilizer addition (typically 0.1 wt% propylene oxide) to suppress exothermic decomposition during transoceanic shipment. Both derivatives display identical storage classification under GHS: Skin Corrosion Category 1B, Eye Damage Category 1, and Aquatic Chronic 3; however, the chloro compound’s lower vapour pressure reduces airborne exposure risk during drum charging operations verified by industrial hygiene monitoring across three contract manufacturing campaigns.
Granulation and Formulation Behaviour Under Thermomechanical Stress
Though primarily an intermediate, 3-chloro-6-methoxycarbonyl-1,2-benzisothiazole occasionally enters downstream formulation when directly incorporated as a crystalline pro-drug precursor in hot-melt extrusion (HME) processes. Differential scanning calorimetry (ASTM D3418-21) at 10 °C min⁻¹ reveals a single sharp endotherm at 81.2 °C (onset) with ΔHfus 28.4 J g⁻¹, consistent across polymorphic screening using ethyl acetate, heptane, and acetone anti-solvent crystallizations, indicating a robust crystalline form without metastable polymorph interference. Processing on a co-rotating twin-screw extruder (L/D 40:1, 16 mm screw diameter, Thermo Fisher Process 11) with a standard polyvinylpyrrolidone-vinyl acetate copolymer (Kollidon VA64) matrix at 15 wt% drug load requires barrel temperature profiling no higher than 75 °C in the conveying zone; excursions to 85 °C caused a 12% decrease in content uniformity (HPLC assay, n=10) accompanied by an increase in the ring-opened hydrolysis product from 0.2% to 2.8%, attributed to residual moisture in the polymer—pre-drying the copolymer at 105 °C under vacuum (−0.08 MPa) for 4 h restored uniformity.
Melt rheology data gathered from an oscillatory frequency sweep (parallel plate, 25 mm, 1 mm gap, 100 °C) indicate Newtonian behaviour across 0.1–100 rad s⁻¹ at shear stresses below 1 kPa. At fill levels exceeding 20 wt%, a yield stress of 3.2 Pa emerged, and dead zones in the feed throat of the extruder resulted in localized thermal degradation, necessitating an upper load limit of 18 wt% for continuous manufacturing lines without side-feeding capability. No crosslinking or discoloration was observed in the presence of titanium dioxide opacifier (2 wt%), ruling out photocatalytic degradation pathways under standard cleanroom lighting.
What Are the Critical Impurity Fate-and-Transport Thresholds in Aqueous Waste Streams?
Production-scale batch manufacturing generates aqueous quench streams containing hydrolysed and sulfonated by-products that challenge conventional activated-sludge wastewater treatment plants (WWTP). The methoxycarbonyl ester hydrolyses at pH > 8.5 to give 3-chloro-1,2-benzisothiazole-6-carboxylic acid, which exhibits an octanol-water partition coefficient (log P, shake-flask method OECD 107) of 0.92 ± 0.05, indicating moderate mobility. Continuous activated-sludge respirometry tests (OECD 209) with domestic mixed liquor suspended solids (2 500 mg L⁻¹) showed 45% inhibition of oxygen uptake rate at a test substance concentration of 100 mg L⁻¹, classifying the hydrolysed wastewater as potentially inhibitory. Consequently, on-site pre-treatment via Fenton oxidation (H₂O₂:Fe²⁺ molar ratio 10:1, pH 3.0, 60 min residence time) is mandated before release to the biological treatment basin. Discharge consent under IED 2010/75/EU for the receiving water body limits total organic carbon (TOC) to 30 mg L⁻¹, achievable only if the Fenton-treated effluent is subsequently passed through a granular activated carbon (GAC) column with an empty bed contact time of 15 min. Breakthrough of the parent compound has been recorded after 1 200 bed volumes on coconut-shell-based GAC (8×30 mesh), mandating bed replacement protocols that add substantial operating cost to campaigns exceeding 500 kg of product.
| Parameter | 3-Chloro-6-Methoxycarbonyl | 3-Bromo-6-Methoxycarbonyl | 6-Methoxycarbonyl-1,2-Benzisothiazole (des-halo) | Test Guideline |
|---|---|---|---|---|
| Daphnia magna acute immobilization, EC₅₀ (48 h) | 12.3 mg L⁻¹ | 8.7 mg L⁻¹ | 34.6 mg L⁻¹ | OECD 202 |
| Algae growth inhibition (Desmodesmus subspicatus), ErC₅₀ (72 h) | 6.1 mg L⁻¹ | 4.2 mg L⁻¹ | 22.0 mg L⁻¹ | OECD 201 |
| Activated sludge respiration inhibition, EC₅₀ (3 h) | 112 mg L⁻¹ | 98 mg L⁻¹ | 210 mg L⁻¹ | OECD 209 |
Parallel attention must be paid to the chlorine substituent’s influence on thermal decomposition off-gases. Thermogravimetric analysis coupled with Fourier-transform infrared spectroscopy (TGA-FTIR) at 20 °C min⁻¹ under nitrogen flow reveals onset of mass loss at 195 °C, with evolution of methyl chloride and sulfur dioxide identified by characteristic IR bands. This profile differs markedly from the des-chloro analogue, which decomposes at 245 °C with CO₂ and methanol as primary volatiles. Pilot-plant vacuum drying at 60 °C and 10 mbar remains well below this threshold, but personnel exposure to fugitive SO₂ during unplanned dryer maintenance has led to the mandatory installation of continuous SO₂ monitors (electrochemical sensor, detection limit 0.1 ppm) in the drying area of the kilo-lab suite.
Pd-Catalysed Suzuki–Miyaura Coupling Protocol Benchmarks
When the synthetic objective is to install a biaryl motif while retaining the 3-chloro handle for subsequent functionalization, the recommended protocol exploits the electron-withdrawing methoxycarbonyl group at C-6 to deactivate the ring sufficiently for selective oxidative addition of a more electron-rich bromide elsewhere in the substrate. Operating with Pd(OAc)₂ (2 mol%) and SPhos (4 mol%) in toluene/water biphasic system (10:1 v/v) with 3.0 equiv. K₂CO₃ at 85 °C, coupling of 4-cyanophenylboronic acid proceeds to 97% conversion in 8 h with <0.5% of the product resulting from chlorine displacement detected by LCMS. Substitution of the ligand to the more electron-rich XPhos accelerates the rate but raises chlorine displacement to 3.2%, a narrow processing window that demands precise temperature control within ±2 °C. At 90 °C or higher, the competing dechlorination pathway becomes kinetically significant, rendering the strategy non-viable. This sensitivity contrasts with the comparable 3-fluoro analogue, which is entirely inert under these conditions but cannot be functionalized under mild conditions later without transition-metal-free photoredox activation (blue LED, 456 nm, Ir(ppy)₃), a protocol that requires specialized equipment and introduces scale-up challenges.
In industrial batch reactors (glass-lined, 200 L), the exotherm observed upon addition of the boronic acid (ΔTad ≈ 18 °C) necessitates controlled dosing over 60 min with jacket cooling to maintain the 85 ± 2 °C target. Any deviation above 88 °C for longer than 5 min leads to irreversible product colour darkening (APHA colour >200) and a 2–3% yield penalty, as recorded across 11 pilot batches. This operational boundary forms the basis for the user requirement specification of the process control system: cascade control of jacket temperature with reactor temperature as the primary variable and feed rate as the manipulated variable.
| Ligand System | Temp (°C) | Main Product Isolated Yield (%) | Chloro Displacement Product (%) | Reaction Time (h) |
|---|---|---|---|---|
| SPhos, 4 mol% | 85 | 93 | 0.4 | 8 |
| XPhos, 4 mol% | 85 | 89 | 3.2 | 5.5 |
| XPhos, 4 mol% | 90 | 81 | 9.7 | 4 |
| RuPhos, 4 mol% | 85 | 91 | 1.8 | 6 |
Neglecting the narrow thermal window and relying on XPhos for faster turnaround has been the root cause of batch rejections in two contract manufacturing organizations in 2022–2023, where the specification for 3-chloro displacement by-product was set at NMT 2.0% but results trended at 3.5–4.1%. Subsequent root cause investigation traced the excursions to a failing thermowell on the reactor, causing a 2.3 °C high bias in the control thermocouple, thus undercooling the vessel. This failure mode underscores the disproportionate impact of minor instrumentation drift on the quality of this particular intermediate.
When Does the 6-Methoxycarbonyl Ester Require in Situ Hydrolysis to Drive Aqueous Solubility?
The ester’s limited water solubility (0.12 mg mL⁻¹ at 25 °C, shake-flask UV/Vis) can be deliberately exploited as a latent solubility switch. In aqueous-phase bioconjugation chemistry targeting lysine residues, pre-hydrolysis of the ester with LiOH in THF/H₂O (3:2) at 0 °C over 20 min yields the corresponding lithium carboxylate, which dissolves readily at 50 mg mL⁻¹ in phosphate-buffered saline (pH 7.4). The chloro substituent remains intact during this hydrolysis, provided the temperature is kept below 5 °C—above 10 °C, competitive hydrolysis of the 3-chloro group to the 3-hydroxy-1,2-benzisothiazole commences (~2% after 30 min). This low-temperature restriction precludes the use of standard jacketed reactors without supplemental cryogenic chilling; a dedicated recirculating chiller capable of delivering silicone oil at −5 °C to the jacket is specified in the SOP. In campaigns where cryogenic infrastructure is unavailable, the procedure is re-engineered to use solid LiOH·H₂O added portionwise to a slurry of the ester in THF at −10 °C, maintaining internal temperature below 2 °C. This modification raises processing time by 45 min but avoids capital expenditure.
Regulatory Filing Support and Comparable Product Differentiation
Documentation packages for drug master file (DMF) submissions referencing 3-chloro-6-methoxycarbonyl-1,2-benzisothiazole as a regulatory starting material for an active pharmaceutical ingredient under ICH Q7 and ICH Q11 must address carryover of the positionally isomeric 3-chloro-5-methoxycarbonyl congener, a common by-product of electrophilic substitution during the construction of the benzoisothiazole core. The 5-isomer, which co-elutes dangerously close to the main peak under multiple isocratic HPLC conditions, is resolved to baseline only with a dedicated gradient (water/acetonitrile 0.1% formic acid from 40% to 70% MeCN over 25 min on a 100 mm × 3.0 mm, 2.7 µm core-shell column). Quantification is essential because the 5-isomer, when carried into an API, produces a final active with a shifted receptor-binding pharmacophore—a finding that led to a Phase I clinical hold issue for a JAK inhibitor developer, reportedly tied to batch contamination by a regioisomeric impurity from an analogous benzisothiazole intermediate. Thus, the generic specification of ≤ 0.15% 5-isomer (by HPLC area) in the supplied compound is a non-negotiable acceptance criterion, which distinguishes this product from lower-priced, bulk-grade materials from non-cGMP sources where isomeric purity is loosely controlled to ≤ 2.0%. This impurity limit is verified during incoming quality audits using a USP Chapter 〈621〉-compliant method with relative response factor correction.
Unlike the corresponding 3-methylthio or 3-phenoxy derivatives, the chloro analogue does not produce genotoxic alkylating metabolites in the standard Ames II assay (OECD 471), enabling a lower alerting structure classification under ICH M7 and simplifying the nitrosamine risk assessment for the downstream API. This toxicological advantage, combined with a solid-state stability of at least 36 months at 25 °C/60% RH (long-term ICH storage condition, aluminium laminate pouch, desiccant), positions the compound as a preferred intermediate in developmental pipelines where avoidable mutagenic impurity alerts would trigger costly Ames-negative confirmatory studies. In contrast, the methylthio analogue flagged in silico as potentially DNA-reactive based on the thioether moiety, requiring batch-specific Ames testing that delayed a supportive IND filing by 4.5 months, as reported in a recent FDA Advisory Committee meeting transcript.
Operational incompatibilities that have led to production deviations include charging the crystalline solid through a manway in high-humidity environments without inert gas purging; one incident captured by deviations log showed moisture-induced caking of the product within the reactor’s isolating valve, leading to a 4 kg material loss and a 48-hour production stoppage. Restructuring the charging procedure to employ a nitrogen-purged glove bag and a PTFE-lined chute eliminated the recurrence. No compatibility issues arise with common gasket materials (EPDM, PTFE-envelope), but accelerated aging tests with Viton® O-rings in methanol at 40 °C for 72 h showed swelling and weight increase of 8.2%, indicating that the ester slowly attacks fluorocarbon elastomers; EPDM is therefore the specified seal in all product-contact equipment.
